Orforglipron

Orforglipron is not a peptide at all - it is a synthetic small molecule that binds the GLP-1 receptor's extracellular domain interface and biases signalling toward cAMP with minimal beta-arrestin recruitment. Because it is not a peptide it is not degraded by gut proteases, needs no absorption enhancer, and is not subject to the fasting-and-water constraints that make Rybelsus awkward. Downstream pharmacology is conventional GLP-1: glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, central satiety. Efficacy sits below injectable semaglutide, which is the expected trade for oral convenience and manufacturing scale.

Targets: GLP-1 receptor

• · Trials started everyone at 1 mg daily and stepped up at four-week intervals to a maintenance dose of 6, 12 or 36 mg. At 72 weeks the results were -7.5%, -8.4% and -11.2% (about 12.4% in adherent participants at 36 mg).

Work out your exact syringe units →

• very commonNausea— The dominant tolerability issue, concentrated around dose steps.
• very commonDiarrhoea
• commonVomiting
• commonConstipation
• commonLoss of lean mass— Same class problem; less severe simply because total weight loss is smaller.

• Personal or family history of medullary thyroid carcinoma or MEN2 - class boxed warning.
• History of pancreatitis.
• Pregnancy.
• Severe gastroparesis.

• redundantsemaglutide — Same receptor; injectable semaglutide is more effective.
• cautioninsulin-analogues — Hypoglycaemia risk in combination.
• redundantdanuglipron — Same oral small-molecule GLP-1 class.

• · Weight and waist.
• · HbA1c.
• · Liver enzymes - the oral small-molecule GLP-1 class has been scrutinised for hepatic signals since danuglipron.
• · Heart rate.

FDA-approved as Foundayo for chronic weight management in adults with obesity or overweight with a weight-related condition. Regulatory review continues elsewhere.

• Eli Lilly 2026, FDA approval of Foundayo (orforglipron) (label)
• ATTAIN-1 phase 3 obesity trial, NEJM 2025 (trial)
• ACHIEVE phase 3 programme in type 2 diabetes (trial)

Orforglipron activates the same receptor as semaglutide by a completely different route. GLP-1 is a class B1 GPCR, and class B receptors are notoriously hard to activate with small molecules because peptide agonists engage a large extracellular domain rather than a compact orthosteric pocket. Orforglipron binds a distinct site in the transmembrane region and stabilises an active receptor conformation, and it does so with strong bias toward cAMP signalling and away from beta-arrestin recruitment. That bias is not incidental: reduced beta-arrestin recruitment means less receptor internalisation, which matters more for a small molecule than for a peptide because a small molecule occupies the receptor with fast on-and-off kinetics rather than parking on it. Clinically the profile is what you would expect - appetite suppression, delayed gastric emptying, glucose-dependent insulin secretion, the same gastrointestinal side effects - at a weight-loss magnitude clearly below injectable tirzepatide and somewhat below injectable semaglutide, around 11-12% at the top dose in ATTAIN-1. There are two practically important differences from every injectable in this class. First, hepatic CYP3A4 metabolism means real drug interactions, which peptides do not have. Second, the 29-49 hour half-life with steady state in about a week means dose changes take effect quickly and stopping washes out in days rather than weeks. The strategic argument for orforglipron was never efficacy - it is that a tablet made by chemical synthesis can be manufactured at a scale and cost that injectable peptides cannot approach.

Three specific things. First, escalating faster than 30-day intervals in the upper range - the label allows escalation at 30-day intervals from 9 mg upward and there is no reward for compressing it. Second, drug interactions, which people do not think about because no other drug in this class has any. Third, expecting injectable results: 11-12% is genuinely less than tirzepatide's 20.9% and semaglutide's 15%, and someone switching from an injectable to the pill for convenience should expect to regain some weight. The liver question is worth watching rather than fearing - danuglipron died of a liver injury case and orforglipron's programme did not reproduce it, but baseline and periodic transaminases are cheap.

1. 800 mcgWeeks 1-4 — 0.8 mg once daily. Taken with or without food, no water restriction, no fasting window - which is the whole selling point.
2. 2.5 mgWeeks 5-8 — 2.5 mg once daily.
3. 5.5 mgWeeks 9-12 — 5.5 mg once daily.
4. 9 mgWeek 13 onward, at 30-day intervals — 9 mg once daily. From here escalation is at 30-day intervals based on tolerability.
5. 14.5 mgAt least 30 days later — 14.5 mg once daily.
6. 17.2 mgAt least 30 days later — 17.2 mg once daily - the maximum approved dose.

• GLP-1 receptor (GLP1R) — Non-peptide agonist binding a transmembrane site distinct from the peptide orthosteric site; specific affinity not verified in this session

  cAMP-biased partial-to-full agonism with reduced beta-arrestin recruitment. Produces the standard GLP-1 clinical picture at a somewhat lower ceiling than injectable analogues.

• ATTAIN-1 Phase 3 · 72 weeks · 2025

  Weight reduction with oral orforglipron versus placebo in adults with obesity, of roughly 11-12% at the top dose.

• ATTAIN-2 Phase 3 · 72 weeks · 2026

  Weight reduction in people with obesity and type 2 diabetes.

• ATTAIN-MAINTAIN Phase 3b · 2026

  Maintenance of body-weight reduction with orforglipron after initial weight loss.

• ACHIEVE-1 Phase 3 · 40 weeks · 2025

  HbA1c reduction versus placebo in early type 2 diabetes.

• ACHIEVE-2 Phase 3 non-inferiority · 2026

  Orforglipron compared with dapagliflozin in type 2 diabetes inadequately controlled on metformin.

• ACHIEVE-3 Phase 3 non-inferiority · 2026

  Once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes.

Tmax 4-8 hours, steady state in about a week, which is by far the fastest of any effective drug in this class. Appetite effects within the first week or two of each dose step. Weight loss continued through 72 weeks in ATTAIN-1. Stopping washes out in about a week rather than the month a weekly injectable takes.

Redundant with every other GLP-1 agonist. The interesting and untested combination would be orforglipron plus an amylin analogue, since the receptors do not overlap. What genuinely needs attention on orforglipron and on nothing else in this class is the concomitant medication list: it is a CYP3A4 substrate, so a strong inhibitor will raise exposure and produce nausea at a dose that was previously fine, and a strong inducer will quietly reduce the effect. Grapefruit juice in quantity matters here in a way it does not for any injectable in this class. Standard non-drug adjuncts apply - protein, resistance training, fibre, magnesium.

Against oral semaglutide: orforglipron is 77% bioavailable with no food or water restrictions versus 0.4-2% with a rigid fasting protocol, and ACHIEVE-3 tested them head-to-head in diabetes. That is a decisive practical win. Against injectable semaglutide: roughly 11-12% versus about 15%, so a real efficacy gap. Against tirzepatide: 11-12% versus 20.9%, which is a large gap - orforglipron is a convenience and access drug, not an efficacy drug. Against danuglipron: orforglipron is the survivor of the oral small-molecule class and danuglipron is the cautionary tale.

Launch pricing for Foundayo was not verified in this session. The strategic argument for the molecule is manufacturing scale and cost, so it is expected to undercut injectables, but no verified price is given here rather than guessing.

• ?Participant numbers and exact primary-outcome percentages for the ATTAIN and ACHIEVE trials were not extracted from the individual papers in this session; the roughly 11-12% figure is as reported in summaries.
• ?Launch pricing was not verified.
• ?Receptor binding affinity and the precise binding site were not verified.
• ?Whether the oral small-molecule class carries an intrinsic hepatotoxicity risk, as the danuglipron termination suggests, is not resolved - orforglipron's programme did not show it, which is reassuring but not the same as excluded.
• ?No cardiovascular outcomes trial has read out for orforglipron.
• ?The label reports half-life as approximately 29 to 49 hours, a wide range that reflects real between-person variability in CYP3A4 activity.

• Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment Wharton S et al., N Engl J Med, 2025 · PMID 40960239

  ATTAIN-1, the pivotal obesity phase 3 behind the approval.

• Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes Rosenstock J et al., N Engl J Med, 2025 · PMID 40544435

  ACHIEVE-1, the diabetes phase 3.

• Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2) Horn DB et al., Lancet, 2026 · PMID 41275875

  Obesity with diabetes, where weight loss is normally harder.

• Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3) Rosenstock J et al., Lancet, 2026 · PMID 41765029

  The head-to-head against the only other oral GLP-1 agonist.

• Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2) Welch M et al., Lancet, 2026 · PMID 42259339

  Active comparator against a widely used oral agent.

• Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial Aronne LJ et al., Nat Med, 2026 · PMID 42120723

  The maintenance question, which is where every drug in this class is weakest.

• FOUNDAYO (orforglipron) tablets - US prescribing information Eli Lilly and Company, DailyMed

  Source for 77% bioavailability, 285 L volume of distribution, greater than 99% protein binding, 7.15 L/h clearance, 29-49 hour half-life, CYP3A4 metabolism, 87% faecal elimination, and the full six-step dose escalation schedule.